<> "The repository administrator has not yet configured an RDF license."^^ . <> . . . "Efficacy of liposomal amphotericin B for treating post-kala-azar dermal leishmaniasis (PKDL): A systematic review and single-arm meta-analysis"^^ . "Background\nPost-kala-azar dermal leishmaniasis (PKDL) is a skin condition that can become a complication in about 15 % of patients who have had kala-azar. Despite its significance, treatment options for PKDL are still limited. This systematic review and meta-analysis aim to evaluate the efficacy of amphotericin B for this condition.\nMethods\nPubMed, Embase, Cochrane, and Web of Science databases were searched for randomized controlled trials (RCTs) that reported the efficacy of Liposomal Amphotericin B in the treatment of PKDL. This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Events per 100 observations with 95 % confidence intervals were performed for outcomes.\nResults\nNine studies with 639 patients were included, the treatment durations ranging from 7 to 60 days. The mean age ranged from 9.2 to 31.0 years, and 359 patients were male. The PKDL treatment with liposomal amphotericin B resulted in a cure rate of 91.36 % (95 % CI: 76.60-97.15). However, a relapse was observed in 11.42 % (95 % CI: 6.20-20.8) of patients. Adverse events were common, with hepatic enzyme elevation (ALT/AST) being the most frequent (61.75 %; 95 % CI: 21.81–90.33), followed by fever in 29.93 % of cases (95 % CI: 5.09–77.30). Among the more serious side effects, decreased serum potassium was observed in 19.27 % (95 % CI: 3.84–58.82), and increased serum creatinine, indicative of nephrotoxicity, occurred in 15.08 % (95 % CI: 3.97–43.27). Nausea or vomiting, although less severe, affected 12.36 % of patients (95 % CI: 4.81–28.25).\nConclusions\nThese findings highlight that while liposomal amphotericin B is a potent therapeutic option for PKDL, its administration requires careful management and clinical vigilance to optimize outcomes and minimize risks."^^ . "2026-02" . . "114" . "2" . . "Diagnostic Microbiology and Infectious Disease"^^ . . . "07328893" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "Deivyd Vieira Silva"^^ . "Cavalcante"^^ . "Deivyd Vieira Silva Cavalcante"^^ . . "Fabiana Castro Porto Silva"^^ . "Lopes"^^ . "Fabiana Castro Porto Silva Lopes"^^ . . "Lyria de Oliveira"^^ . "Rosa"^^ . "Lyria de Oliveira Rosa"^^ . . "Noor"^^ . "Husain"^^ . "Noor Husain"^^ . . "Luciana"^^ . "Borrigueiro"^^ . "Luciana Borrigueiro"^^ . . "Lilia Maria Lima"^^ . "de Oliveira"^^ . "Lilia Maria Lima de Oliveira"^^ . . "Sarah Soares"^^ . "Amorim"^^ . "Sarah Soares Amorim"^^ . . "Ana Clara Felix de Farias"^^ . "Santos"^^ . "Ana Clara Felix de Farias Santos"^^ . . "Christian"^^ . "Ndikuryayo"^^ . "Christian Ndikuryayo"^^ . . "Lalit"^^ . "Mohan"^^ . "Lalit Mohan"^^ . . "Beatriz Ximenes"^^ . "Mendes"^^ . "Beatriz Ximenes Mendes"^^ . . . . . "HTML Summary of #17868 \n\nEfficacy of liposomal amphotericin B for treating post-kala-azar dermal leishmaniasis (PKDL): A systematic review and single-arm meta-analysis\n\n" . "text/html" . . . "Biomedicine"@en . "Biomedicina"@es . .